Literature DB >> 14729288

Somatic complaints and isoniazid (INH) side effects in Latino adolescents with latent tuberculosis infection (LTBI).

J Berg1, E J Blumberg, C L Sipan, L S Friedman, N J Kelley, A Y Vera, C R Hofstetter, M F Hovell.   

Abstract

This study examined the potential effects of INH side effects and non-specific somatic complaints on medication adherence in 96 Latino adolescents participating in a controlled trial designed to increase isoniazid (INH) adherence. These participants (who received usual medical care) were interviewed monthly over 9 months. Participants were questioned regarding medication taking, the frequency of 15 INH-related side effects from the Physician's Desk Reference (PDR) [1], and 21 non-specific somatic complaints. Participants were aged 12-19 years, 53.1% were male, 66.7% were born in Mexico, 73% had no health insurance, and 52.5% were classified as bicultural. Approximately 70% of participants experienced at least one side effect during the trial. Side effects that occurred while taking INH were not significantly related to total number of pills taken; somatic complaints that occurred during 9 months of INH were significantly negatively related to cumulative adherence. Females reported significantly more somatic complaints at baseline than males.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14729288     DOI: 10.1016/s0738-3991(02)00268-9

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  8 in total

1.  Management of latent tuberculous infection in Norway in 2009: a descriptive cross-sectional study.

Authors:  A I M Olsen; H E Andersen; J Aßmus; J A Djupvik; G Gran; K Skaug; O Mørkve
Journal:  Public Health Action       Date:  2013-06-21

2.  Predictors of adherence to latent tuberculosis infection therapy in Latino immigrants.

Authors:  Rita L Ailinger; Pat Black; Nga Nguyen; Howard Lasus
Journal:  J Community Health Nurs       Date:  2007       Impact factor: 0.974

Review 3.  Recent tuberculosis advances in Latin America.

Authors:  Tom Pelly; David A J Moore; Robert Gilman; Carlton Evans
Journal:  Curr Opin Infect Dis       Date:  2004-10       Impact factor: 4.915

Review 4.  Patient adherence to tuberculosis treatment: a systematic review of qualitative research.

Authors:  Salla A Munro; Simon A Lewin; Helen J Smith; Mark E Engel; Atle Fretheim; Jimmy Volmink
Journal:  PLoS Med       Date:  2007-07-24       Impact factor: 11.069

5.  A Nano-MgO and Ionic Liquid-Catalyzed 'Green' Synthesis Protocol for the Development of Adamantyl-Imidazolo-Thiadiazoles as Anti-Tuberculosis Agents Targeting Sterol 14α-Demethylase (CYP51).

Authors:  Sebastian Anusha; Baburajeev Cp; Chakrabhavi Dhananjaya Mohan; Jessin Mathai; Shobith Rangappa; Surender Mohan; Shardul Paricharak; Lewis Mervin; Julian E Fuchs; Mahedra M; Andreas Bender; Kanchugarakoppal S Rangappa
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

6.  Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).

Authors:  Yin Yin Xia; Dai Yu Hu; Fei Ying Liu; Xiao Meng Wang; Yan Li Yuan; De Hua Tu; Yi Xin Chen; Lin Zhou; Li Zhen Zhu; Wei Wei Gao; Hong Yuan Wang; Da Fang Chen; Li Yang; Ping Ping He; Xiao Ting Li; Ying Jian He; Feng Sun; Si Yan Zhan
Journal:  BMC Public Health       Date:  2010-05-21       Impact factor: 3.295

7.  Pharmacovigilance and moroccan tuberculosis public program: current situation.

Authors:  Driss Soussi Tanani; Amina Tebaa; Raja Benkirane; Kenza Bennani; Ghali Iraqi; Abdelmajid Soulaymani; Rachida Soulaymani Bencheikh
Journal:  Tuberc Res Treat       Date:  2014-06-12

Review 8.  Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review.

Authors:  Anke L Stuurman; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anouk M Oordt-Speets; Andreas Sandgren; Marieke J van der Werf
Journal:  BMC Infect Dis       Date:  2016-06-08       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.